PreNAtAL

9

• Detects fetal trisomies of chromosomes 21, 13 and 18• Detects microdeletion syndromes• Identifies fetal sex and reports the most common aneuploidies

of sex chromosomes

• Test entirely carried out in Spain• Results in 7 working days

*See Informed Consent for exceptions

Non-invasive prenatal screening from maternal blood

What are the requirements to carry outthetestTrisoNIM®Advance?

A reliable and efficient method for those mothers wishing to know iftheir fetus is likely to suffer from a frequent syndrome without riskingtheir pregnancy.

(*) Calculations based on a population study of over 211,000 samples ofpregnant women.

security parameters of the analysis

chromosome

T21 (Down’s Syndrome) 99,65% <0,01%

T18 (Edwards’ Syndrome) 99,66% <0,02%

T13 (Patau’s Syndrome) 100% <0,02%

X0 (Turner Syndrome) >95% –

Chromosome Y detection >98% –

detectingcapacity (*)

False positivepredictive values (*)

Down´s syndrome is a congenital abnormality caused by trisomy(three copies instead of two) of chromosome 21.Those affected by this syndrome can suffer from mental delay and other complications. There are also other trisomies causing significant complications in affected individuals, i.e. Edwards´ syndrome (trisomy of chromosome 18) and Patau´s syndrome (trisomy of chromosome 13).

Alterations can occur in the number of sex chromosomes, known as sex aneuploidies. Turner (X0) and Klinefelter (XXY) syndromes are among the most common. Individuals affected by these have fertility problems and alterations in the development of the sexual organs, among other complications. In some cases, they also suffer from mental delay.

Down´s syndrome appears in approximately one per 700 births.Edwards´ and Patau´s syndromes occur in about one per 5,000 and 16,000 births, respectively. Sex aneuploidies appear in one per 500 male and in one per 850 female births.

There are also genetic syndromes caused by a loss of small portions of the genome (called microdeletions). The most frequent being the syndrome of micro-deletion 1p36 and 2q33.1 or the Cri-du-Chat syndrome. Individuals affected by these syndromes present health problems at their birth, such as malformations in several organs and mental delay. Unlike the trisomies, there is no proven link between these syndromes and advanced maternal age. The test TrisoNIM®Advance can also exclude the presence of these three syndromes in maternal blood.

Why is it important to carry outnon-invasiveprenatalscreening?

The incidence of these alterations increases exponentially with the mother´s pregnancy age, from the age of 35. This risk is determined in the first trimester of pregnancy, on the basis of three factors: age of the pregnant woman, biochemical markers in maternal blood and anomalies in the fetus observed during an ultrasound scan.

It is important to remember that a high risk result with TrisoNIM®Advance has to be confirmed by an amniocentesis, an invasive technique, involving the extraction of amniotic fluid.

NIMGenetics offers this validation free of charge with KaryoNIM®Prenatal, a test capable of excluding, fast and efficiently, up to 124 syndromes.

To be pregnant from week 10 onwards, asconfirmed by ultrasound scan.

To be in compliance with your doctor and tosign an informed consent.

To allow the collection of 10 ml of blood.

1.

2.

3.

PreNAtAL

10

Once the risk for the fetus to develop the syndromes previouslyreferred to is determined, the gynecologist can recommend a test to confirm this. The only option until now was to perform anamniocentesis; an invasive technique which represents a risk ofmiscarriage of up to 1%. However, it is now possible to avoid this risk in all those cases where amniocentesis was necessary thanks to a screening test that only requires the collection of a blood sample.

NIMGenetics, a leading company in genetic diagnosis, offers itsTrisoNIM® Advance test; a fast, secure and effective prenatal screening method. TrisoNIM®Advance provides early detection of trisomies in chromosomes 21, 18 and 13, responsible for Down´s, Edwards´ and Patau´s syndromes, through a simple analysis of maternal blood.

Moreover, TrisoNIM®Advance can report the presence of chromosome Y in the sample, revealing fetal sex, and also the presence of the most common sex chromosome abnormalities. It can also exclude three microdeletion syndromes.

security and efficacy in prenatal genetic diagnostics

The diagnosis is based on a study of fetal DNA

(deoxyribonucleic acid) present in maternal

blood, which detects the presence of the three

syndromes, with a reliability of almost 100%.

The non-invasive testthat offers you security

and peace of mind

What are the advantages ofTrisoNIM®Advance?✓ Indicates the absence of Down’s, Edwards’ and Patau’s

syndromes, with a 99.65%accuracyormore.

✓ Avoids carrying out unnecessary amniocentesis reducing the risk of a miscarriage associated with this invasive technique. It is the best alternative when invasive tests are avoidable.

✓ Excludes the presence of microdeletion syndromes such as: microdeletion1p36,microdeletion2q33.1andCri-du-chat.

✓ Is able to detect the presence of chromosome Y with a sensitivityof98%,allowing evaluation of fetal sex.

✓ Reports the most common aneuploidies of the sex chromosomes.

✓ Only10mlofmaternalbloodare necessary.

✓ Can be performed from week10ofpregnancy.

✓ Can be used with women receiving oocytes.

✓ Can be used in twin pregnancies.